| Dealing with time in health economic evaluation: methodological issues and recommendations for practice JF O’Mahony, AT Newall, J van Rosmalen Pharmacoeconomics 33, 1255-1268, 2015 | 88 | 2015 |
| Some inconsistencies in NICE’s consideration of social values M Paulden, JF O’Mahony, AJ Culyer, C McCabe Pharmacoeconomics 32, 1043-1053, 2014 | 63 | 2014 |
| Cervical screening during the COVID-19 pandemic: optimising recovery strategies A Castanon, M Rebolj, EA Burger, IMCM de Kok, MA Smith, SJB Hanley, ... The Lancet Public Health 6 (7), e522-e527, 2021 | 55 | 2021 |
| Determinants of change in the cost-effectiveness threshold M Paulden, J O’Mahony, C McCabe Medical Decision Making 37 (2), 264-276, 2017 | 55 | 2017 |
| The Irish cost-effectiveness threshold: does it support rational rationing or might it lead to unintended harm to Ireland’s health system? JF O’Mahony, D Coughlan Pharmacoeconomics 34, 5-11, 2016 | 51 | 2016 |
| NICE’s selective application of differential discounting: ambiguous, inconsistent, and unjustified JF O’Mahony, M Paulden Value in Health 17 (5), 493-496, 2014 | 49 | 2014 |
| Preeclampsia Prevention Using Routine Versus Screening Test–Indicated Aspirin in Low-Risk Women: A Cost-Effectiveness Analysis F Mone, JF O’Mahony, E Tyrrell, C Mulcahy, P McParland, F Breathnach, ... Hypertension 72 (6), 1391-1396, 2018 | 48 | 2018 |
| Challenges in cost-effectiveness analysis modelling of HPV vaccines in low-and middle-income countries: a systematic review and practice recommendations OI Ekwunife, JF O’Mahony, A Gerber Grote, C Mosch, T Paeck, ... Pharmacoeconomics 35, 65-82, 2017 | 41 | 2017 |
| A mathematical approach for evaluating Markov models in continuous time without discrete-event simulation J van Rosmalen, M Toy, JF O’Mahony Medical Decision Making 33 (6), 767-779, 2013 | 32 | 2013 |
| Discounting the recommendations of the second panel on cost-effectiveness in health and medicine M Paulden, JF O’Mahony, C McCabe Pharmacoeconomics 35 (1), 5-13, 2017 | 31 | 2017 |
| Evaluation of the effectiveness and cost-effectiveness of personalized surveillance after colorectal adenomatous polypectomy E McFerran, JF O'Mahony, R Fallis, D McVicar, AG Zauber, F Kee Epidemiologic reviews 39 (1), 148-160, 2017 | 30 | 2017 |
| Beware of kinked frontiers: a systematic review of the choice of comparator strategies in cost-effectiveness analyses of human papillomavirus testing in cervical screening JF O’Mahony, SK Naber, C Normand, L Sharp, JJ O’Leary, IMCM de Kok Value in Health 18 (8), 1138-1151, 2015 | 28 | 2015 |
| Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information JF O’Mahony, J Van Rosmalen, AG Zauber, M Van Ballegooijen Medical Decision Making 33 (3), 407-414, 2013 | 28 | 2013 |
| Early detection of HPV-associated oropharyngeal cancer M Lechner, CE Breeze, JF O'Mahony, L Masterson Lancet 393 (10186), 2123-2123, 2019 | 26 | 2019 |
| Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts JF O'Mahony, IMCM de Kok, J van Rosmalen, JDF Habbema, W Brouwer, ... Value in Health 14 (4), 438-442, 2011 | 26 | 2011 |
| Beneluxa: what are the prospects for collective bargaining on pharmaceutical prices given diverse health technology assessment processes? JF O’Mahony PharmacoEconomics 37 (5), 627-630, 2019 | 21 | 2019 |
| Surveying the cost-effectiveness of the 20 procedures with the largest public health services waiting lists in Ireland: implications for Ireland’s cost-effectiveness threshold TC Chen, D Wanniarachige, S Murphy, K Lockhart, J O’Mahony Value in Health 21 (8), 897-904, 2018 | 19 | 2018 |
| Systematic review of costs and effects of self-management interventions for chronic musculoskeletal pain: spotlight on analytic perspective and outcomes assessment MJ Hernon, AM Hall, JF O’Mahony, C Normand, DA Hurley Physical Therapy 97 (10), 998-1019, 2017 | 17 | 2017 |
| The influence of disease risk on the optimal time interval between screens for the early detection of cancer: a mathematical approach JF O’Mahony, J van Rosmalen, NA Mushkudiani, FW Goudsmit, ... Medical Decision Making 35 (2), 183-195, 2015 | 13 | 2015 |
| The limitations of Icers in screening interventions and the relative net benefit alternative JF O’Mahony Value in Health 18 (7), A705, 2015 | 12 | 2015 |
Charles NormandEmeritus Professor, Trinity College Dublin, Professor, King's College London在 tcd.ie 的电子邮件经过验证
